NASDAQ:CSTL Castle Biosciences Q3 2026 Earnings Date & Estimates $33.19 -1.18 (-3.43%) Closing price 04:00 PM EasternExtended Trading$33.18 -0.01 (-0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Castle Biosciences is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Castle Biosciences in Q3 2026Castle Biosciences is expected to post earnings of -$0.3544 per share on revenue of $92.41 million. In the same quarter a year earlier Castle Biosciences reported -$0.02 per share on revenue of $80.55 million. Castle Biosciences last reported on July 30, 2026, posting -$0.07 per share and beating the -$0.4070 consensus estimate. Castle Biosciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.3544Expected Revenue$92.41 millionPrior-Year EPS-$0.02Prior-Year Revenue$80.55 millionExpected Revenue Growth+14.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.07 (Beat by +$0.3370)Last Quarter Revenue$99.86 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Castle Biosciences Q3 2026 Earnings FAQ When does Castle Biosciences report Q3 2026 earnings? Castle Biosciences (NASDAQ:CSTL) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Castle Biosciences' Q3 2026 earnings call? Castle Biosciences' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Castle Biosciences? Analysts expect Castle Biosciences to post earnings of -$0.3544 per share for Q3 2026. How much revenue is Castle Biosciences expected to report? The consensus revenue estimate for Castle Biosciences is $92.41 million for Q3 2026. Castle Biosciences Earnings HeadlinesCastle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026October 15, 2026 | prnewswire.comCastle Biosciences, Inc. Announces New Data from Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test at ACG 2026October 12, 2026 | marketscreener.comMYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 22 at 1:00 AM | Profits Run (Ad)Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells InvestorsOctober 12, 2026 | gurufocus.comACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusOctober 12, 2026 | prnewswire.comNew Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)October 9, 2026 | finance.yahoo.comSee More Castle Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Castle Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Castle Biosciences and other key companies, straight to your email. Email Address About Castle BiosciencesCastle Biosciences (NASDAQ:CSTL) is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment. Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma. Castle Biosciences also offers MyPath Melanoma, which assists in evaluating difficult-to-diagnose melanocytic lesions, and TissueCypher, a prognostic test intended to identify progression risk in patients with Barrett’s esophagus. Founded in 2008, Castle Biosciences is headquartered in Friendswood, Texas, and provides its diagnostic services primarily to physicians and healthcare providers in the United States. The company became publicly traded on the Nasdaq in 2019. Derek Maetzold serves as the company’s president and chief executive officer.View Castle Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Texas Paused Data Center Hookups—2 Power Stocks Are Waiting on the VerdictIs Texas Instruments Setting Up for Its Next Big Breakout?Lam Research's Earnings Beat Wasn't the Real Story—Its 2027 Outlook WasTesla’s Flying-Car Hype Hits an Earnings Reality CheckMeta Bounces Back in Q3, But the Bigger Test Comes in 2027Cologuard Is Working—So Why Isn’t Abbott Stock?Pegasystems' Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Upcoming Earnings ENI (10/23/2026)SLB (10/23/2026)American Express (10/23/2026)Infosys (10/23/2026)Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
